Literature DB >> 30827925

Increased mortality in non-alcoholic fatty liver disease with chronic kidney disease is explained by metabolic comorbidities.

Kristina Önnerhag1, Karl Dreja2, Peter M Nilsson3, Stefan Lindgren4.   

Abstract

BACKGROUND: There is a close association between non-alcoholic fatty liver disease (NAFLD) and prevalent chronic kidney disease (CKD). Few longitudinal studies exist. No previous study has investigated to what extent CKD affects mortality in biopsy-proven NAFLD. Our aim was to investigate the long-term risk of developing CKD in biopsy-proven NAFLD and its effect on mortality.
METHODS: Patients with biopsy-proven NAFLD diagnosed in 1978-2006 in Malmö, Sweden were included. Estimated glomerular filtration rate (eGFR) at baseline and last follow-up was calculated with the CKD-EPI equation. CKD 3-5 (< 60 mL/min/1.73 m2) was classified as CKD. Hospital medical records were extensively scrutinized from inclusion to endpoint (death or end of 2016). The prevalence of CKD was compared to a control group from the population-based prospective cohort Malmö Preventive Project (MPP).
RESULTS: 120 patients with biopsy-proven NAFLD were included. Mean age was 52.5 years and mean follow-up time 19.5 years. At baseline CKD prevalence in NAFLD was only significantly higher in the highest age group compared to controls (> 55 years, 25% vs. 9.5%, P = 0.003), and no significant difference was seen at follow-up (in total 37.5% vs. 30.8%, P = 0.124). NAFLD patients with long-term CKD had significantly higher crude overall mortality rate than NAFLD patients without CKD (P < 0.001). Regression analyses revealed that this increased mortality risk was explained by an increased prevalence of metabolic comorbidities (including diabetes mellitus), not CKD.
CONCLUSION: Mortality risk is significantly increased in NAFLD patients with long-term CKD due to metabolic comorbidities, not influenced by CKD per se.
Copyright © 2019 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Chronic kidney disease; Epidemiology, liver cirrhosis; Liver fibrosis; Metabolic syndrome; Mortality; non-alcoholic fatty liver disease

Year:  2019        PMID: 30827925     DOI: 10.1016/j.clinre.2019.02.004

Source DB:  PubMed          Journal:  Clin Res Hepatol Gastroenterol        ISSN: 2210-7401            Impact factor:   2.947


  8 in total

Review 1.  Pathogenesis of non-alcoholic fatty liver disease and implications on cardiovascular outcomes in liver transplantation.

Authors:  Benedict J Maliakkal
Journal:  Transl Gastroenterol Hepatol       Date:  2020-07-05

Review 2.  Association of metabolic dysfunction-associated fatty liver disease with kidney disease.

Authors:  Ting-Yao Wang; Rui-Fang Wang; Zhi-Ying Bu; Giovanni Targher; Christopher D Byrne; Dan-Qin Sun; Ming-Hua Zheng
Journal:  Nat Rev Nephrol       Date:  2022-01-10       Impact factor: 28.314

Review 3.  Non-alcoholic fatty liver and chronic kidney disease: Retrospect, introspect, and prospect.

Authors:  Rajiv Heda; Masahiko Yazawa; Michelle Shi; Madhu Bhaskaran; Fuad Zain Aloor; Paul J Thuluvath; Sanjaya K Satapathy
Journal:  World J Gastroenterol       Date:  2021-05-07       Impact factor: 5.742

4.  Study on the correlation between urinary retinol-binding protein and nonalcoholic fatty liver disease.

Authors:  Chuang Li; Weiwei Kong; Lixia Kang; Tiehan Zhang; Weiqun Zhang; Weidong Wang
Journal:  J Med Biochem       Date:  2021-01-26       Impact factor: 3.402

5.  COVID-19 risk, disparities and outcomes in patients with chronic liver disease in the United States.

Authors:  QuanQiu Wang; Pamela B Davis; Rong Xu
Journal:  EClinicalMedicine       Date:  2020-12-22

6.  Distinct Cause of Death Profiles of Hospitalized Non-alcoholic Fatty Liver Disease: A 10 Years' Cross-Sectional Multicenter Study in China.

Authors:  Yansong Lin; Xiaorong Gong; Xin Li; Congxiang Shao; Tingfeng Wu; Minrui Li; Fuxi Li; Qianqian Ma; Junzhao Ye; Bihui Zhong
Journal:  Front Med (Lausanne)       Date:  2021-01-12

Review 7.  Diabetic Kidney Disease, Cardiovascular Disease and Non-Alcoholic Fatty Liver Disease: A New Triumvirate?

Authors:  Carolina M Perdomo; Nuria Garcia-Fernandez; Javier Escalada
Journal:  J Clin Med       Date:  2021-05-10       Impact factor: 4.241

8.  Systematic review of the impact of non-alcoholic fatty liver disease on mortality and adverse clinical outcomes for individuals with chronic kidney disease.

Authors:  Theresa Hydes; Ryan Buchanan; Oliver J Kennedy; Simon Fraser; Julie Parkes; Paul Roderick
Journal:  BMJ Open       Date:  2020-09-28       Impact factor: 2.692

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.